Home › Acute Lymphoblastic Leukemia › NCT03568266
Pharmacogenomics of Asparaginase Induced Hepatotoxicity
Pharmacogenomics of Age-Specific, Asparaginase-Induced Hepatotoxicity in Patients With Acute Lymphoblastic Leukemia
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Newly diagnosed with acute lymphoblastic leukemia (ALL) - no prior treatment for ALL * Receiving asparaginase as part of the primary treatment regimen * Ability to understand and the willingness to sign a written informed consent * For retrospective recruitment, those who have received asparaginase between 2012 and 2017; and are current patients of University of Southern California (USC) Exclusion Criteria: * Patients who are unable to give informed consent
About the study
This pilot trial studies the impact of genetic information on developing liver damage caused by asparaginase in participants with newly diagnosed acute lymphoblastic leukemia. Testing saliva samples may help doctors find certain genetic markers that may predict whether participants will tolerate asparaginase, which is given as part of clinical care for acute lymphoblastic leukemia.
What is being tested
- Biospecimen Collection (procedure)
Sponsor: University of Southern California · Participants: 500 · Started: May 22, 2018
Contact the study team
- Christine Duran · Phone: 323-865-0371
Official record on ClinicalTrials.gov — NCT03568266
Locations in the U.S.
| California | Los Angeles General Medical Center, Los Angeles USC / Norris Comprehensive Cancer Center, Los Angeles |
Conditions
From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.